

AroCell appoints new CEO

AroCell AB today announces a safe and smooth transition to a new CEO of the company.

Former CFO Anders Hultman has been appointed new CEO. During the more than two years he has been at AroCell, Anders has done an exceptional job together with the former CEO Michael Brobjer, which enables a simple and smooth transition to the new role. Anders is very well acquainted with the company's strategies and plans to take the AroCell TK 210 ELISA to the next level. In addition to a solid experience as CFO, Anders has the business acumen needed for a demanding CEO assignment. He has previous experience of successfully running both listed and unlisted companies in various industries.

"I am honored to take over as CEO after Michael Brobjer. AroCell has a fantastic product and is in an important and interesting phase where full focus is on the strengthened commercialization of AroCell TK 210 ELISA. I look forward to leading AroCell to the next phase together with our professional team ", says CEO Anders Hultman.

Former CEO Michael Brobjer has resigned at his request. He and his family are going on a longer sailing voyage. Michael resigns today as CEO and thus enables a smooth transition for the new CEO Anders Hultman. During the remaining time at the company, Michael will focus on the launch of AroCell TK 210 ELISA in the US prior to the FDA approval of AroCell's 510(k) submission. Michael will work his last day at AroCell on April 30th but will continue as a consultant for AroCell.

"I look forward with great excitement to AroCell's continued journey and am convinced of its success. At the same time, I am on my way to the adventure of my life, something that we in the family promised each other many years ago. It will be very exciting to follow AroCell's continued development from the oceans ", says former CEO Michael Brobjer.

"Michael Brobjer has made a great contribution to AroCell and through his leadership taken the company to a new level. I am pleased that through the appointment of Anders Hultman, we can confidently ensure that AroCell continues to pursue its successful work to offer a better tool to support oncologists in the treatment of cancer while placing further focus on our US launch," said Claes Post, Chairman of the Board at AroCell.

Contacts

Claes Post, Chairman of the Board
Phone: +46(0)18 50 30 20
E-mail: claes.post@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-01-11 10:05 CET.

Attachments

[AroCell appoints new CEO](#)